TYSABRI® (natalizumab) is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis. TYSABRI increases the risk of PML. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. See important information regarding the risk of PML with TYSABRI.

You are leaving this site. This link will take you to a website that is outside the control of Biogen Idec. We provide links as a public service and for informational purposes only. We do not make or imply any endorsement of external web sites.

Click Cancel to return or OK to continue.


You have clicked on a link that will take you out of this website.

Click Cancel to return or OK to continue.


Blank Overlay Used To Show Alert Messages Automatically

Submission Is In Progress
One Moment Please.

Accepting outside referrals indicates an infusion site is willing to accept patients outside of their current practice. If they do not accept outside referrals then they only accept patients who are part of their current practice.


We look forward to sharing exclusive information and updates about TYSABRI.


Your profile is updated.